Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on ...

supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective radioimmunotherapy based on a pan-tumor predictive biomarker. “With RAD204, we hope to provide an ...

My research focuses on the development of a theranostic platform approach for pretargeted radioimmunotherapy (PRIT) of solid human tumors. We call this strategy “DOTA-PRIT,” which is short for “DOTA ...

Correcting & Replacing: Y-mAbs Therapeutics, Inc. is re-issuing in entirety its press release, originally issued on January 10, 2025 at 7:05 a.m. ET, to correct a scrivener's error in the presentation ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

(the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based ...

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization ...

Dr. Ajay Gopal develops new targeted treatments for patients with lymphoma. One of his focus areas is radioimmunotherapy, a precision-targeted form of radiation designed to kill cancer cells while ...

23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the“Company” or“Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel ...